X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (52) 52
Publication (7) 7
Book / eBook (6) 6
Newspaper Article (4) 4
Conference Proceeding (3) 3
Dissertation (2) 2
Book Review (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (27) 27
humans (22) 22
oncology (20) 20
female (18) 18
hematology (18) 18
fludarabine (17) 17
male (16) 16
rituximab (16) 16
cyclophosphamide (14) 14
adult (13) 13
aged (13) 13
leukemia, lymphocytic, chronic, b-cell - drug therapy (13) 13
middle aged (13) 13
survival (12) 12
chemoimmunotherapy (11) 11
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
abridged index medicus (9) 9
chemotherapy (9) 9
cyclophosphamide - administration & dosage (9) 9
disease-free survival (9) 9
prognosis (9) 9
vidarabine - analogs & derivatives (9) 9
cll (8) 8
leukemia, lymphocytic, chronic, b-cell - mortality (8) 8
previously untreated patients (8) 8
therapy (8) 8
vidarabine - administration & dosage (8) 8
chronic lymphatic leukemia (7) 7
clinical trials (7) 7
treatment outcome (7) 7
aged, 80 and over (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
cancer (6) 6
chronic lymphocytic leukemia (6) 6
follow-up studies (6) 6
initial therapy (6) 6
leukemia, lymphocytic, chronic, b-cell - pathology (6) 6
antibodies, monoclonal, murine-derived - administration & dosage (5) 5
chlorambucil (5) 5
combination (5) 5
diagnosis (5) 5
leukemia (5) 5
lymphatic leukemia (5) 5
minimal residual disease (5) 5
mutation (5) 5
neutropenia (5) 5
open-label (5) 5
patients (5) 5
phase-ii trial (5) 5
remission induction (5) 5
rituximab - administration & dosage (5) 5
bone marrow (4) 4
care and treatment (4) 4
chronic lymphocytic-leukemia (4) 4
progression (4) 4
risk factors (4) 4
alemtuzumab (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
bendamustine (3) 3
clinical trials, phase iii as topic (3) 3
development and progression (3) 3
disease progression (3) 3
drug administration schedule (3) 3
drug therapy (3) 3
expression (3) 3
flow cytometry (3) 3
fludarabine plus cyclophosphamide (3) 3
further section · weitere sektionen (3) 3
guidelines (3) 3
ibrutinib (3) 3
immunotherapy (3) 3
leukemia, lymphocytic, chronic, b-cell - diagnosis (3) 3
leukemia, lymphocytic, chronic, b-cell - epidemiology (3) 3
leukemia, lymphocytic, chronic, b-cell - therapy (3) 3
lung neoplasms - genetics (3) 3
progression-free (3) 3
recurrence (3) 3
remission (3) 3
survival rate (3) 3
trial (3) 3
1st-line therapy (2) 2
aberrations (2) 2
analysis (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
article (2) 2
b-cell lymphoma (2) 2
bendamustine hydrochloride - administration & dosage (2) 2
biomarkers, tumor - genetics (2) 2
blood (2) 2
campath-1h (2) 2
case report (2) 2
cell number (2) 2
chromosome aberrations (2) 2
combined modality therapy (2) 2
comorbidity (2) 2
cyclophosphamide - adverse effects (2) 2
dna mutational analysis (2) 2
doxorubicin - administration & dosage (2) 2
endometrial cancer (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 01/2016, Volume 127, Issue 2, pp. 208 - 215
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 7, pp. 928 - 942
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
BLOOD, ISSN 0006-4971, 05/2017, Volume 129, Issue 19, pp. 2702 - 2705
Journal Article
by Dandona, Paresh and Mathieu, Chantal and Phillip, Moshe and Hansen, Lars and Griffen, Steven C and Tschöpe, Diethelm and Thorén, Fredrik and Xu, John and Langkilde, Anna Maria and Proietto, Joseph and Stranks, Stephen and Chen, Roger and O'Neal, David and Pape, Alexia and Forbes, Mark and Morbey, Claire and Luger, Anton and Hanusch, Ursula and Schnack, Christoph and Fliesser-Goerzer, Evelyn and Hoelzl, Bertram and Ebenbichler, Christoph and Prager, Rudolf and Van Gaal, Luc and Vercammen, Chris and Scheen, Andre and Duyck, Francis and Nobels, Frank and Ruige, Johannes and Aggarwal, Naresh and Woo, Vincent and St-Pierre, Bruno and Dumas, Richard and Hramiak, Irene and Elliott, Thomas and Krarup Hansen, Troels and Henriksen, Jan Erik and Gram, Jeppe and Lihn, Aina and Bruun, Jens and Saltevo, Juha and Taurio, Jyrki and Strand, Jorma and Valle, Timo and Nieminen, Sakari and Pietilainen, Kirsi and Guerci, Bruno and Hadjadj, Samy and Cariou, Bertrand and Verges, Bruno and Borot, Sophie and Penfornis, Alfred and Schaum, Thomas and Tschoepe, Diethelm and Marck, Cornelia and Horacek, Thomas and Rose, Ludger and Klausmann, Gerhard and Luedemann, Joerg and Appelt, Steffi and Aigner, Ulrich and Goebel, Rolf and Behnke, Thomas and Ziegler, Anette-Gabriele and Peterfai, Eva and Kerenyi, Zsuzsanna and Oroszlan, Tamas and Kiss, Gyula G and Konyves, Laszlo and Piros, Gyorgyi and Mosenzon, Ofri and Shehadeh, Naim and Adawi, Faiad and Wainstein, Julio and Dotta, Francesco and Piatti, Piermarco and Genovese, Stefano and Consoli, Agostino and Di Bartolo, Paolo and Mannucci, Edoardo and Giordano, Carla and Lapolla, Annunziata and Aguilar, Carlos and Esteban, Alberto and Ruiz, Bazzoni and Ramirez, Guillermo Mondragon and Pelayo Orozco, Emilia and Alejandro, Carlos and de Alba, Stobschinski and Medina Pech, Carlos and Garza Ruiz, Jose and Sauque Reyna, Leobardo and Llamas Esperon, Guillermo and Nevarez Ruiz, Luis Alejandro and Vidrio Velazquez, Maricela and Flores Lozano, Fernando and Gonzalez Gonzalez, Jose Gerardo and Garcia-Hernandez, Pedro Alberto and Araujo-Silva, Roberto and Villeda - Espinosa, Efrain and ... and DEPICT-1 Investigators
The Lancet Diabetes & Endocrinology, ISSN 2213-8587, 11/2017, Volume 5, Issue 11, pp. 864 - 876
Journal Article
Cancer, ISSN 0008-543X, 06/2013, Volume 119, Issue 12, pp. 2258 - 2267
BACKGROUND Scarce systematic trial data have prevented uniform therapeutic guidelines for T-cell prolymphocytic leukemia (T-PLL). A central need in this... 
T‐cell prolymphocytic leukemia | T‐cell leukemia 1 | mature T‐cell leukemia/lymphoma | alemtuzumab, fludarabine, mitoxantrone, and cyclophosphamide chemotherapy | T-cell leukemia 1 | T-cell prolymphocytic leukemia | mature T-cell leukemia/lymphoma | mitoxantrone | and cyclophosphamide chemotherapy | CAMPATH-1H | DIAGNOSIS | PENTOSTATIN | CARDIAC TOXICITY | lymphoma | COMBINATION | TRANSPLANTATION | PHASE-II TRIAL | THERAPY | alemtuzumab | ONCOLOGY | fludarabine | CHRONIC LYMPHOCYTIC-LEUKEMIA | mature T-cell leukemia | MYCOSIS FUNGOIDES/SEZARY-SYNDROME | Proto-Oncogene Proteins - metabolism | Cyclophosphamide - administration & dosage | Mitoxantrone - administration & dosage | Humans | Middle Aged | Vidarabine - adverse effects | Leukemia, Prolymphocytic, T-Cell - genetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Treatment Outcome | Vidarabine - analogs & derivatives | Alemtuzumab | Remission Induction | Disease-Free Survival | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Leukemia, Prolymphocytic, T-Cell - drug therapy | Proto-Oncogene Proteins - analysis | Chromosome Aberrations | Adult | Female | Aged | Leukemia, Prolymphocytic, T-Cell - mortality | Vidarabine - administration & dosage | Chemotherapy, Combination | Research | Lymphocytic leukemia | Drug therapy | Patient outcomes | Methods | Index Medicus | Abridged Index Medicus
Journal Article